APA (7th ed.) Citation

Karthaus, M., & Hofheinz, R. (2016). Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. British journal of cancer, 115(10), . https://doi.org/10.1038/bjc.2016.343

Chicago Style (17th ed.) Citation

Karthaus, Meinolf, and Ralf-Dieter Hofheinz. "Impact of Tumour RAS/BRAF Status in a First-line Study of Panitumumab + FOLFIRI in Patients with Metastatic Colorectal Cancer." British Journal of Cancer 115, no. 10 (2016). https://doi.org/10.1038/bjc.2016.343.

MLA (9th ed.) Citation

Karthaus, Meinolf, and Ralf-Dieter Hofheinz. "Impact of Tumour RAS/BRAF Status in a First-line Study of Panitumumab + FOLFIRI in Patients with Metastatic Colorectal Cancer." British Journal of Cancer, vol. 115, no. 10, 2016, https://doi.org/10.1038/bjc.2016.343.